LivaNova PLC - Ordinary Shares (LIVN) News
LivaNova PLC - Ordinary Shares (LIVN)
Today's Latest Price: $54.25 USD
Updated Nov 27 1:00pm
Add LIVN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
Filter LIVN News Items
LIVN News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LIVN News From Around the Web
Below are the latest news stories about LivaNova PLC that investors may wish to consider to help them evaluate LIVN as an investment opportunity.
Artificial Cardiopulmonary Machine Market 2020-28 plays a crucial role of the heart and lungs during surgical procedures| LivaNova, Terumo CV Group, Getinge, Medtronic, Tianjin Medical, Braile BiomedicaArtificial heart-lung machine, commonly known as Artificial Cardiopulmonary Machine or cardiopulmonary bypass pump, is used to take the role of the heart and lungs during any cardiovascular surgical procedure. The Artificial Cardiopulmonary Machine Market report is an extensive, proficient and |
LivaNova to Host Conference Call for Third Quarter 2020 ResultsLONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12 p.m. London (8 a.m. EDT). |
LivaNova to Present at the Baird 2020 Global Healthcare ConferenceLONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC announced Damien McDonald, CEO, will present at the Baird 2020 Global Healthcare Conference on Thursday, Sept. 10 at 9:05 a.m. EDT. |
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova poster at ESC 2020 to share potential for autonomic regulation therapy to improve heart failure patients' long-term cardiovascular function. |
Global Neurology Devices Market (2019 to 2025) - Featuring LivaNova, Magstim & Medtronic Among Others - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)--The "Neurology Devices Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The global neurology devices market is estimated to witness significant growth during the forecast period. Increasing demand for neurostimulation devices is one of the factors that are driving the market growth. Rising prevalence of neurological disorders, including Parkinson's and Alzheimer's disease has led the adoption of neurostimulation devices. In addition, rising |
LivaNova PLC (LIVN) CEO Damien McDonald on Q2 2020 Results - Earnings Call TranscriptLivaNova PLC (LIVN) Q2 2020 Earnings Conference Call July 29, 2020 07:00 AM ET Company Participants Matthew Dodds - Senior Vice President of Corporate Development Damien McDonald - Chief Executive Officer Thad Huston - Chief Financial Officer Melissa Farina - Vice President of Investor Relations Conference Call Participants Matthew O'Brien... |
LivaNova Reports Second Quarter 2020 ResultsLONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020. |
Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out forLivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Did Hedge Funds Make The Right Call On LivaNova PLC (LIVN) ?The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […] |
LivaNova Announces Commercial Launch of Perceval Plus Aortic Heart Valve in EuropeLONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today announced the advanced Perceval® Plus sutureless surgical aortic heart valve is now available for commercial release in Europe. |
